Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-12-25 Remuneration Information
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2025年限制性股票激励计划首次授予部分激励对象名单
Remuneration Information Classification · 95% confidence The document is a detailed list of recipients for a restricted stock incentive plan for the year 2025, including names, positions, and stock allocation details. It is issued by the company's board and dated December 25, 2025. The content focuses on the allocation of stock incentives to directors, senior management, and key personnel, which is a form of remuneration information. There is no indication that this is a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. The document is not a regulatory filing or announcement of a report publication. Given the focus on stock incentives and compensation details, the most appropriate classification is Remuneration Information (DEF 14A). The document length is short and specific to compensation, supporting this classification with high confidence.
2025-12-25 Chinese
2025年限制性股票激励计划实施管理办法
Governance Information Classification · 95% confidence The document is titled as the "2025 Restricted Stock Incentive Plan Implementation Management Measures" for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the governance structure, procedures for granting and vesting restricted stock, rights and obligations of the company and incentive recipients, conditions for plan changes and termination, accounting treatment, and legal compliance. The content focuses on the company's internal stock incentive plan and governance related to equity compensation. It is not a financial report, earnings release, or regulatory announcement. It is a detailed governance and management document related to stock incentives, which fits best under Governance Information (CGR). The document length (6309 characters) and detailed procedural content confirm it is a substantive governance report rather than a brief announcement or certification.
2025-12-25 Chinese
关于募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the delay of a fundraising investment project. It details the background of the fundraising, the original and adjusted investment plans, reasons for the delay, and the company's measures to ensure completion. The document includes references to regulatory approvals, board meeting decisions, and sponsor opinions. It does not contain financial statements or detailed financial performance data but rather focuses on the status and changes related to the use of raised funds. The document length is 4091 characters, which is relatively short and typical for an announcement rather than a full report. The content fits the description of a Capital/Financing Update (CAP) as it provides updates on the company's fundraising project and its timeline changes. Therefore, the appropriate classification is CAP with high confidence.
2025-12-12 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司募投项目延期的核查意见
Regulatory Filings
2025-12-12 Chinese
自愿披露关于公司产品续约纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the renewal of a product's inclusion in the National Medical Insurance Directory. It provides details about the product, its classification, payment standards, and the impact on the company. The document is short (971 characters) and serves as a formal announcement rather than a detailed financial report or regulatory filing. It does not contain financial statements, management discussion, or detailed governance information. It is not an earnings release, capital update, or legal proceeding report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product inclusion in a government insurance list, which affects the company's business but is not a financial report or other specific filing type.
2025-12-08 Chinese
关于参加2025年上海辖区上市公司三季报集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. about their participation in the 2025 Shanghai-listed companies third quarter collective earnings explanation meeting. It provides details about the meeting time, location, format, and how investors can participate and ask questions. It references the company's 2025 third quarter report already published on October 31, 2025, but this document itself is not the report or the transcript of the meeting. It is an announcement about the upcoming investor presentation related to the third quarter results. The document length is short (1495 characters) and it mainly serves to inform investors about the event rather than providing financial data or detailed analysis. Therefore, it fits best as an Investor Presentation (IP) announcement or related to an investor presentation event. Given the content focuses on the upcoming interactive meeting to discuss quarterly results, the classification as Investor Presentation (IP) is appropriate with high confidence.
2025-11-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.